Evidence map›Paper›PMID 42344864›Full record

ArticleJournal of surgical case reports2026

Conversion surgery after response to zolbetuximab-based chemotherapy in Claudin 18.2-positive gastric cancer: a case report.

Shinya Ohno, Tomonari Suetsugu, Hironobu Takeuchi, Sho Miyazaki, Tatsuki Kawahara, Kazuo Yamamoto, Shunya Kiriyama, Kakeru Tawada, Yoshinori Iwata, Shuji Komori and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shinya OhnoDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Tomonari SuetsuguDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Hironobu TakeuchiDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Sho MiyazakiDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Tatsuki KawaharaDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Kazuo YamamotoDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Shunya KiriyamaDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.ORCID https://orcid.org/0009-0005-5628-7631
Kakeru TawadaDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Yoshinori IwataDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Shuji KomoriDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Chihiro TanakaDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Narutoshi NagaoDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.
Masahiko KawaiDepartment of Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noisshiki, Gifu-city, Gifu-prefecture 500-8717, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zolbetuximab, a monoclonal antibody targeting Claudin (CLDN)18.2, has demonstrated clinical benefit in advanced gastric cancer, although reports of conversion surgery remain limited. A 59-year-old man with CLDN18.2-positive stage IV gastric cancer and suspected peritoneal dissemination received zolbetuximab with capecitabine and oxaliplatin. After six courses, imaging showed marked tumor regression. Staging laparoscopy revealed no peritoneal metastasis, and laparoscopic distal gastrectomy achieved R0 resection. Histopathology demonstrated a grade 2b response, and the final stage was ypStage IB. The patient remains recurrence-free at 12 months. Although conversion surgery was feasible, significant intraoperative bleeding occurred, likely due to treatment-related fibrosis and tissue fragility. This case suggests that zolbetuximab-based chemotherapy may enable conversion surgery in selected patients. Careful perioperative management is essential, and further studies are needed.

Indexed as

CLDN18.2-positive gastric cancerconversion surgeryrobotic-assisted surgeryZolbetuximab

Identifiers

PMID42344864
PMCPMC13289852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.